ViiV Healthcare
 | This article contains promotional content. (June 2023) |
 | |
| Company type | Joint venture |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 2009 |
| Headquarters | London, England, UK |
Area served | Worldwide |
Key people | Deborah Waterhouse (CEO) |
| Products | Pharmaceuticals |
| Owners | |
Number of employees | c. 1,100 (2023) |
| Website | viivhealthcare |
ViiV Healthcare (/ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS. Its global headquarters is located in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company.[1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi.[2] According to The Financial Times, the company's co-ownership structure may change depending on the achievement of certain milestones.[1]
ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.[3]
ViiV Healthcare's global headquarters are in Brentford, Greater London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[4]
Products
[edit]The company markets 17 products:[5]
- Nucleoside reverse transcriptase inhibitors (NRTIs):
- abacavir (brand name Ziagen)
- lamivudine (brand names Epivir and 3TC)
- zidovudine (brand name Retrovir and AZT)
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
- delavirdine (brand name Rescriptor, no longer available[6])
- Attachment inhibitors
- fostemsavir (brand name Rukobia)
- Integrase strand transfer inhibitors (INSTIs):
- dolutegravir (brand name Tivicay)
- cabotegravir (brand names Apretude [as a single agent indicated for PrEP]; and Vocabria/Cabenuva [when co-administered with rilpivirine for HIV treatment – in partnership with Janssen Pharmaceuticals])
- Protease inhibitors:
- fosamprenavir (brand names Lexiva and Telzir)
- nelfinavir (brand name Viracept)
- Entry inhibitors:
- maraviroc (brand names Selzentry and Celsentri)
- Antiretroviral fixed-dose combinations, including several single-pill regimens:
- abacavir/lamivudine (brand names Epzicom and Kivexa)
- abacavir/lamivudine/zidovudine (brand name Trizivir)
- lamivudine/zidovudine (brand name Combivir)
- abacavir/dolutegravir/lamivudine (brand name Triumeq)
- dolutegravir/lamivudine (brand name Dovato)
- dolutegravir/rilpivirine (brand name Juluca – in partnership with Janssen Pharmaceuticals)
Treatment access programs
[edit]ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low- and middle-income countries, as well as all of Sub-Saharan Africa.[7]
The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[7][8]
In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV.[9]
See also
[edit]References
[edit]- ^ a b Jacks, Andrew "GSK and Pfizer to Merge HIV Portfolios Financial Times. 16 April 2010 (subscription required)
- ^ "Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. Retrieved 7 March 2014.
- ^ "ViiV vows joint venture will help fight HIV". Financial Times. London. Retrieved 3 November 2023.
- ^ "ViiV Healthcare Company Website. About Us – Locations" Archived 9 December 2010 at the Wayback Machine Accessed 13 October 2010
- ^ "Our HIV medicines". Retrieved 10 March 2022.
- ^ "Generic Rescriptor Availability". Drugs.com. Retrieved 10 March 2022.
- ^ a b "ViiV Healthcare Company Website. We Improve Access to Our Medicines" Accessed 12 January 2014
- ^ Reuters "Glaxo, Pfizer JV Opens HIV Pipeline to Generic Companies" Africa – the Good News. 19 July 2010
- ^ "ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV". Olean Times Herald. Retrieved 3 March 2020.
| Subsidiaries |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
